NO20044054L - Administrering av midler for behandling av betennelse - Google Patents

Administrering av midler for behandling av betennelse

Info

Publication number
NO20044054L
NO20044054L NO20044054A NO20044054A NO20044054L NO 20044054 L NO20044054 L NO 20044054L NO 20044054 A NO20044054 A NO 20044054A NO 20044054 A NO20044054 A NO 20044054A NO 20044054 L NO20044054 L NO 20044054L
Authority
NO
Norway
Prior art keywords
inflammation
administration
agents
treatment
Prior art date
Application number
NO20044054A
Other languages
English (en)
Other versions
NO336235B1 (no
Inventor
Ted Yednock
Julie Taylor
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20044054(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of NO20044054L publication Critical patent/NO20044054L/no
Publication of NO336235B1 publication Critical patent/NO336235B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
NO20044054A 2002-02-25 2004-09-24 Anvendelse av et middel som inhiberer alfa-4-integrin eller en dimer som omfatter alfa-4-integrinen i fremstillingen av et medikament for vedvarende anvendelse ved terapeutisk behandling av patologisk inflammasjon forårsaket av multippel sklerose eller en inflammatorisk sykdom i magetarmkanalen. NO336235B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36013402P 2002-02-25 2002-02-25
US37450102P 2002-04-23 2002-04-23
PCT/US2003/005421 WO2003072040A2 (en) 2002-02-25 2003-02-25 Administration of agents for the treatment of inflammation

Publications (2)

Publication Number Publication Date
NO20044054L true NO20044054L (no) 2004-11-24
NO336235B1 NO336235B1 (no) 2015-06-22

Family

ID=27767592

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044054A NO336235B1 (no) 2002-02-25 2004-09-24 Anvendelse av et middel som inhiberer alfa-4-integrin eller en dimer som omfatter alfa-4-integrinen i fremstillingen av et medikament for vedvarende anvendelse ved terapeutisk behandling av patologisk inflammasjon forårsaket av multippel sklerose eller en inflammatorisk sykdom i magetarmkanalen.

Country Status (28)

Country Link
US (7) US20040009169A1 (no)
EP (6) EP2289941A3 (no)
JP (3) JP2005526045A (no)
KR (1) KR20040105740A (no)
CN (1) CN1310678C (no)
AR (1) AR038605A1 (no)
AT (1) ATE512163T1 (no)
AU (2) AU2003213231A1 (no)
BR (1) BR0307975A (no)
CA (1) CA2477178A1 (no)
CO (1) CO5611176A2 (no)
CY (1) CY1111787T1 (no)
DK (2) DK2336184T3 (no)
ES (1) ES2531852T3 (no)
HK (1) HK1073997A1 (no)
IL (3) IL163725A0 (no)
MX (1) MXPA04008267A (no)
MY (1) MY157727A (no)
NO (1) NO336235B1 (no)
NZ (3) NZ579583A (no)
PL (1) PL215263B1 (no)
PT (2) PT1485127E (no)
RU (1) RU2359697C2 (no)
SA (1) SA03240276A (no)
SI (2) SI2336184T1 (no)
TW (2) TWI346558B (no)
WO (1) WO2003072040A2 (no)
ZA (1) ZA200407406B (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2336184T1 (sl) 2002-02-25 2015-04-30 Biogen Idec Ma Inc. Dajanje sredstev za zdravljenje vnetij
AU2003261071C1 (en) 2002-03-13 2008-12-11 Biogen Idec Ma Inc. Anti-AlphavBeta6 antibodies
KR101260497B1 (ko) * 2003-01-24 2013-09-12 엘란 파마슈티칼스, 인크. 수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료 및 조성물
CA2515444C (en) 2003-02-10 2014-04-01 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
AU2004251754A1 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
CN1956738B (zh) 2004-01-09 2013-05-29 辉瑞大药厂 MAdCAM抗体
JP4996261B2 (ja) * 2004-02-06 2012-08-08 エラン ファーマシューティカルズ，インコーポレイテッド 腫瘍および転移性疾患を処置するための方法および組成物
AU2011213878B2 (en) * 2004-04-01 2012-06-14 Biogen Ma Inc. Steroid sparing agents and methods of using same
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
AU2011232775B2 (en) * 2004-08-20 2013-11-28 Biogen Ma Inc. Extended Treatment of Multiple Sclerosis
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
EP1827491A4 (en) * 2004-11-19 2010-07-14 Biogen Idec Inc TREATMENT OF MULTIPLE SCLEROSIS
AU2012202575B2 (en) * 2004-11-19 2014-11-20 Biogen Ma Inc. Treatment for Multiple Sclerosis
US20090169477A1 (en) * 2004-12-03 2009-07-02 Michael Panzara Delaying or preventing onset of multiple sclerosis
PT1835922E (pt) * 2004-12-22 2009-07-08 Merck Serono Sa Tratamento combinado para esclerose múltipla
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
US20080261894A1 (en) * 2005-02-17 2008-10-23 Rivka Kreitman Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis
JP2008537595A (ja) 2005-04-04 2008-09-18 バイオジェン アイデック エムエイ インコーポレイテッド 治療タンパク質に対する免疫反応を評価するための方法および生成物
AU2012202823B2 (en) * 2005-04-04 2014-09-25 Biogen Ma Inc. Methods and Products for Evaluating an Immune Response to a Therapeutic Protein
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2007007160A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat fever
CA3127202A1 (en) 2006-02-28 2007-09-07 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
JP2009531304A (ja) * 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
CN101437541A (zh) 2006-03-03 2009-05-20 伊兰药品公司 用那他珠单抗治疗炎性疾病和自身免疫病的方法
JP2009542810A (ja) 2006-07-10 2009-12-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｍａｄ４欠損癌の増殖を阻害するための組成物および方法
EP2053961A4 (en) * 2006-08-09 2013-05-01 Biogen Idec Inc METHOD FOR DISPENSING A MEDICAMENT
EP2109480B1 (en) 2006-12-07 2017-06-28 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin
BRPI0901298A2 (pt) 2009-04-06 2011-01-04 Ems Sa derivados ftalimìdicos de compostos antiinflamatórios não-esteróide e/ou moduladores de tnf-(alfa), processo de sua obtenção, composições farmacêuticas contendo os mesmos e seus usos no tratamento de doenças inflamatórias
CA2758548A1 (en) * 2009-04-17 2010-10-21 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
US20120258093A1 (en) * 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
EP3349010A1 (en) 2009-10-11 2018-07-18 Biogen MA Inc. Anti-vla-4 related assays
DK3339865T5 (da) 2010-01-11 2023-03-20 Biogen Ma Inc Assay for jc-virus-antistoffer
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
LT2558499T (lt) 2010-04-16 2017-07-25 Biogen Ma Inc. Antikūnai prieš vla-4
JP5847188B2 (ja) 2010-10-25 2016-01-20 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ｓＶＣＡＭおよび／またはｓＭＡｄＣＡＭレベルの差を関連付けることにより、アルファ−４インテグリン活性の差を決定するための方法
CN114642731A (zh) * 2011-03-31 2022-06-21 豪夫迈·罗氏有限公司 施用β7整联蛋白拮抗剂的方法
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EA032625B1 (ru) 2011-05-02 2019-06-28 Милленниум Фармасьютикалз, Инк. КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА
PT2802319T (pt) * 2012-01-12 2018-01-29 Pharma Two B Ltd Terapia de combinação de dose fixada da doença de parkinson
EP2928374B1 (en) * 2012-12-05 2019-07-24 Theranos IP Company, LLC Device for bodily fluid sample collection
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHODS OF EVALUATION RISK OF DEVELOPMENT OF PML
WO2015051152A1 (en) * 2013-10-03 2015-04-09 Leuvas Therapeutics Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
HUE051014T2 (hu) * 2014-04-04 2021-01-28 Taiho Pharmaceutical Co Ltd Taxán vegyületet tartalmazó tumorellenes gyógyszer és tumorellenes hatáserõsítõ
RU2016147569A (ru) * 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
EP3978530A1 (en) * 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
WO2017066590A1 (en) * 2015-10-16 2017-04-20 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
CR20200076A (es) 2017-07-14 2020-06-10 Pfizer ANTICUERPOS CONTRA MAdCAM
US11312775B2 (en) 2017-07-20 2022-04-26 University Of Virginia Patent Foundation Methods for treatment or prevention of a neurological immunity disorder
MA52249A (fr) 2018-04-12 2021-05-05 Morphic Therapeutic Inc Antagonistes de l'intégrine humaine (alpha4) (beta7)
US20210147547A1 (en) * 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
KR20220102669A (ko) 2019-10-16 2022-07-20 모픽 테라퓨틱, 인코포레이티드 인간 인테그린 α4β7의 억제
WO2022160323A1 (zh) * 2021-01-31 2022-08-04 兰州大学 核苷类似物在制备预防或治疗胃肠道疾病药物中的应用
EP4323407A1 (en) 2021-04-13 2024-02-21 Biogen MA Inc. Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome
CA3173754A1 (en) * 2021-09-03 2024-03-02 Pliant Therapeutics, Inc. Therapeutic modulation of integrins

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH037237A (ja) * 1989-03-14 1991-01-14 Sandoz Ag シクロスポリン類投与の新規用途および治療手段
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5730978A (en) * 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5260210A (en) * 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
SE464961B (sv) 1989-11-15 1991-07-08 Volvo Ab Ledprotes, i synnerhet foer fingerleder
DE59008157D1 (de) 1989-11-20 1995-02-09 Wolfgang Becker Verfahren zur herstellung einer zahnprothese.
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
EP0531472B1 (en) 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0625912B1 (en) 1992-02-12 1997-04-16 Biogen, Inc. Treatment for inflammatory bowel disease
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5336894A (en) 1992-04-21 1994-08-09 The United States Of America As Represented By The Secretary Of The Air Force Universal infrared heat source controller
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
HU220799B1 (hu) 1994-01-25 2002-05-28 Elan Pharmaceuticals, Inc. Humanizált antitestek VLA-4 leukocita adhéziós molekula ellen
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
US6001809A (en) 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
AU2964295A (en) 1994-07-11 1996-02-09 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
ES2203722T3 (es) 1995-11-10 2004-04-16 Elan Corporation, Plc Peptidos que faccilitan el transporte a traves de tejidos y metodos de identificarlos y usarlos.
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
DE69833654T2 (de) 1997-05-29 2006-12-14 Merck & Co., Inc. (A New Jersey Corp.) Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
WO2000044408A2 (en) 1999-01-29 2000-08-03 Millennium Pharmaceuticals, Inc. Method of treating demyelinating inflammatory disease using ccr1 antagonists
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
CA2409515C (en) 2000-05-10 2015-11-24 Mayo Foundation For Medical Education & Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
SI2336184T1 (sl) * 2002-02-25 2015-04-30 Biogen Idec Ma Inc. Dajanje sredstev za zdravljenje vnetij
KR101260497B1 (ko) * 2003-01-24 2013-09-12 엘란 파마슈티칼스, 인크. 수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료 및 조성물
CA2515444C (en) * 2003-02-10 2014-04-01 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
US20090169477A1 (en) * 2004-12-03 2009-07-02 Michael Panzara Delaying or preventing onset of multiple sclerosis
WO2006112951A2 (en) * 2005-03-03 2006-10-26 Seedlings Life Science Ventures, Llc Method of risk management for patients undergoing natalizumab treatment
JP2008537595A (ja) * 2005-04-04 2008-09-18 バイオジェン アイデック エムエイ インコーポレイテッド 治療タンパク質に対する免疫反応を評価するための方法および生成物
CA3127202A1 (en) * 2006-02-28 2007-09-07 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab

Also Published As

Publication number Publication date
US20110064729A1 (en) 2011-03-17
EP1485127B1 (en) 2011-06-08
JP2011140493A (ja) 2011-07-21
RU2004128454A (ru) 2005-05-10
MXPA04008267A (es) 2004-11-10
EP2360185A2 (en) 2011-08-24
BR0307975A (pt) 2005-01-11
CY1111787T1 (el) 2015-10-07
AR038605A1 (es) 2005-01-19
PL215263B1 (pl) 2013-11-29
ATE512163T1 (de) 2011-06-15
CA2477178A1 (en) 2003-09-04
JP2005526045A (ja) 2005-09-02
EP2336184A3 (en) 2012-01-11
US20070025989A1 (en) 2007-02-01
IL163725A0 (en) 2005-12-18
US20220162321A1 (en) 2022-05-26
DK1485127T3 (da) 2011-10-03
HK1073997A1 (en) 2005-10-28
US20040009169A1 (en) 2004-01-15
SI1485127T1 (sl) 2011-09-30
KR20040105740A (ko) 2004-12-16
NZ579583A (en) 2011-04-29
NO336235B1 (no) 2015-06-22
AU2003213231A1 (en) 2003-09-09
TW200400047A (en) 2004-01-01
US20170306026A1 (en) 2017-10-26
AU2009201587A1 (en) 2009-05-14
NZ535320A (en) 2008-05-30
TWI346558B (en) 2011-08-11
US20150152182A1 (en) 2015-06-04
DK2336184T3 (en) 2015-02-16
SA03240276A (ar) 2005-12-03
ES2531852T3 (es) 2015-03-20
EP2336184A2 (en) 2011-06-22
CO5611176A2 (es) 2006-02-28
US20200148773A1 (en) 2020-05-14
US11248051B2 (en) 2022-02-15
IL163725A (en) 2013-07-31
WO2003072040A3 (en) 2004-05-21
EP1485127A4 (en) 2006-02-01
PL372306A1 (en) 2005-07-11
IL203515A (en) 2015-10-29
EP2289941A2 (en) 2011-03-02
CN1646163A (zh) 2005-07-27
TW201125584A (en) 2011-08-01
SI2336184T1 (sl) 2015-04-30
EP2360185A3 (en) 2012-01-11
NZ591635A (en) 2012-06-29
CN1310678C (zh) 2007-04-18
PT2336184E (pt) 2015-03-09
MY157727A (en) 2016-07-15
JP2015042629A (ja) 2015-03-05
ZA200407406B (en) 2005-11-30
RU2359697C2 (ru) 2009-06-27
EP2336184B1 (en) 2014-12-03
EP3173426A1 (en) 2017-05-31
PT1485127E (pt) 2011-09-07
EP3674322A1 (en) 2020-07-01
EP2289941A3 (en) 2012-01-18
AU2009201587B2 (en) 2012-01-19
WO2003072040A2 (en) 2003-09-04
US7807167B2 (en) 2010-10-05
EP1485127A2 (en) 2004-12-15

Similar Documents

Publication Publication Date Title
NO20044054L (no) Administrering av midler for behandling av betennelse
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
CY2016031I2 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
NO20031442L (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
NO20040097L (no) Kombinasjoner for behandling av inflammatoriske forstyrrelser
NO20053623D0 (no) Derivater av prostaglandiner for behandling av abdominalt ubehag
CY2018006I1 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
IS7825A (is) Meðferðarfræðileg meðhöndlun
NO20045554L (no) Fremgangsmate for behandling av diabetes
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
NO20033804D0 (no) Karbamatforbindelser for behandling av smerte
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
NO20043576L (no) Pharmaceutical formulation comprising melatonin
NO20043445L (no) Kombinasjonsterapi for behandling av bakterielle infeksjoner
NO20020784D0 (no) Medikament for behandling av brudd
NO20040497L (no) Amidinderivater for behandling av amyloidose
IS6020A (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
NO20033160D0 (no) Anordning for behandling av gravann
NO20042166L (no) Kombinasjonsterapi for behandling av sykdom
ITMI20022263A1 (it) Composizioni per il trattamento delle emorroidi.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BIOGEN IDEC MA INC, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BIOGEN MA INC., US

MK1K Patent expired